Episode 63

Precision Pioneers EP 7: Dr Vineeta Agarwala on investing in the future of precision medicine at the a16z bio fund


June 7th, 2021

46 mins 7 secs

Your Host

About this Episode

Can the speed and success of COVID-19 trials teach us how to run other trials 5x faster going forward? Can polygenic risk scores be effectively integrated into healthcare systems? Why do 'unique datasets' hold the key to future drug discovery? And why is there a disparity between precision medicine development in cancer and all other disease areas? Dr Vineeta Agarwala, General Partner at the Andreessen Horowitz Bio Fund, answers all these questions and more as she discusses the future of biotech and genomic medicine with Patrick.